Boldaxyl 300 Steroid Profile
Active life: 15 days
Administration: Injectable solution in oil
Dose: 200 to 600 mg/week
Water retention: Moderate
High blood pressure: Rare
Liver damage: No
DHT conversion: Low
Hormone production suppression: Medium
Boldaxyl (also known under the trade name Equipoise, Boldabol) is an anabolic steroid developed for veterinary use. The drug is designed as a long-acting version of Methandrostenolone, but the result was a steroid, which has a completely different properties, despite the similarity of chemical molecules. Boldenone is a Dianabol molecule which is devoid of 17-alpha-methyl group (this part of the Dianabol molecule allows passage through the liver without being destroyed). If we compare the performance of Boldaxyl and Dianabol, the results obtained in weight gain and increasing strength are almost the same.
Boldaxyl is chemically a testosterone molecule that has a double bond between the 1st and 2nd carbon atom. This modification made Boldaxyl the same potent as testosterone, for anabolic properties, whereas androgenic properties of the drug are expressed by two times weaker. However, practice shows that Equipoise allows you to get lower results than an equivalent amount of testosterone.
Boldaxyl is often compared to Nandrolone, obviously, it is associated with the Dan Duchaine‘s book, where the author draws parallels between the two drugs, noting, however, that a stronger anabolic is Boldenone. In fact Boldenone and Nandrolone are different.
Nandrolone is a progestin and a 19-nor steroid whereas Boldenone is closer to testosterone. Dan Duchaine later changed his mind with regard to the similarity of drugs, but on the forums, you can still find messages that are not recommended to combine Boldenone and Nandrolone because of the similarities. Dan Duchaine also writes that Equipoise is more suitable for producing relief and venous muscles than for a set of muscle mass.
Kalpa Pharmaceuticals Boldaxyl comes in 10 mL multi-dose vial, 300 mg/mL.
Boldaxyl Dosage: 600 mg per week or more.